Article
HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
Anticancer research - 1 Jul 2017
Yotsumoto Fusanori, Fukagawa Satoshi, Miyata Kohei, Nam Sung Ouk, Katsuda Takahiro, Miyahara Daisuke, Odawara Takashi, Manabe Sadao, Ishikawa Toyokazu, Yasunaga Shin'ichiro, Miyamoto Shingo
Abstract excerpt
Advanced lung cancer is one of the most lethal malignancies. Many anticancer agents have been developed for lung cancer with epidermal growth factor receptor (EGFR) mutations, but its prognosis remains extremely poor. The development of molecularly-targeted therapies is required for patients with lung cancer with secondary mutation of the EGFR gene. In this study, in order to assess the validity of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.